Maria Dobek Sells 2,038 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) VP Maria Dobek sold 2,038 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Janux Therapeutics Stock Down 1.5%

Shares of JANX opened at $14.39 on Friday. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The firm has a market capitalization of $877.50 million, a price-to-earnings ratio of -7.82 and a beta of 2.58. The stock’s 50-day moving average price is $14.43 and its 200 day moving average price is $17.04.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Aberdeen Group plc boosted its holdings in shares of Janux Therapeutics by 21.1% in the 3rd quarter. Aberdeen Group plc now owns 345,476 shares of the company’s stock worth $8,443,000 after acquiring an additional 60,188 shares in the last quarter. Readystate Asset Management LP lifted its holdings in Janux Therapeutics by 38.0% during the 3rd quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after buying an additional 264,423 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Janux Therapeutics by 175.1% during the 4th quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock worth $1,101,000 after buying an additional 50,802 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Janux Therapeutics during the 4th quarter worth $536,000. Finally, Rhenman & Partners Asset Management AB lifted its holdings in Janux Therapeutics by 81.6% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 100,127 shares of the company’s stock worth $2,447,000 after buying an additional 45,000 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics News Summary

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush reaffirmed a Buy rating on Janux Therapeutics, which helps reinforce bullish sentiment around the stock. Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
• Positive Sentiment: HC Wainwright raised earnings estimates across several future periods, including 2026 through 2029, suggesting improving expectations for Janux Therapeutics’ financial outlook.
• Positive Sentiment: The analyst also increased near-term EPS forecasts for Q2, Q3, and Q4 2026, which can be interpreted as a sign that operating trends may be improving.
• Neutral Sentiment: Vice President Maria Dobek sold 2,038 shares at an average price of $14.17, a modest insider transaction that may be viewed as a small overhang but not necessarily a major red flag. SEC Form 4 filing
• Neutral Sentiment: Janux remains unprofitable, and even the upgraded forecasts still point to losses, which keeps the long-term risk profile elevated.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald lowered their price objective on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Piper Sandler lowered their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings upgraded Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Evercore set a $22.00 price objective on Janux Therapeutics in a research note on Monday. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.85.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.